GAIA’s mHealth products have demonstrated their clinical benefit in numerous RCTs. Our products meet all regulatory and data protection requirements in the EU and US.
GAIA is a European pioneer in mobile health (mHealth), launching its first programme successfully in 2001.
Our mission: Designing and developing software-based medical devices that offer physicians, therapists and patients the same effect sizes, similar safety profiles, and equal levels of convenience as found in well-developed pharmaceutical solutions.
Our multidisciplinary expert teams cover all competencies required to develop, launch and maintain top-of-class products for major markets: Experienced physicians and psychotherapists, clinical scientists experienced in orchestrating Phase II & III trials, IT and software engineers, regulatory affairs experts as well as market access specialists.
One of our most researched products is deprexis®, the online programme for the treatment of depression. deprexis® has been shown to effectively reduce symptoms of depression in 5 randomized controlled trials (RCTs) as well as in real-life clinical settings, with effect sizes similar to those of antidepressants. For more information, please visit deprexis.com.
Our current R&D pipeline with 7,000 patients in clinical trials covers a wide range of phase II and phase III next generation mHealth programmes, for conditions such as borderline personality disorder (priovi®), generalized anxiety disorder / panic disorder / social phobia (velibra®), fatigue in multiple sclerosis (elevida®), or compliance support (covivio®), among others. For more detailed information regarding our pipeline or requests for research and development partnerships, please contact us directly via mail or phone.
Our expert system technology platform broca® forms the backbone of more than 70 mHealth training, education and therapeutic intervention programmes developed and implemented to date. Started as a joint venture with the Airbus group, broca® has set healthcare industry benchmarks for individualized web based solutions. Our programmes simulate 1:1 coaching, training or therapy sessions, in which a virtual expert and a user interact intensively to achieve a particular goal. Similar to a chess computer, broca® programmes facilitate rapid learning and deep skill acquisition in a dynamic and individual flow. The programmes engage users continuously in interactive exercises and guide them, step-by-step, towards specific learning goals and therapeutic targets.
The latest version of our broca® 4.0 software affords the flexibility to run our highly individualised programs on nearly all web-compatible devices. Consistent with a “quantified-self” approach, we can now capture and visually display a host of performance parameters, assessed either directly within the systems or via interfaces with fitness wristbands, medical devices or other applications. Our broca® 4.0 software enables us to integrate such parameters in our individualised, dialogue-based programs, allowing us to produce even more targeted and custom-tailored interventions. The new platform is CE-certified, FDA approvable and offers many options for health care professionals wishing to monitor and support their patients’ program use.
Not only do we develop our own new and innovative products, but we also share our expertise and experience with selected customers – offering a broad variety of services and consulting relating to mHealth, e.g. risk assessment for your mHealth products/Apps, CE-certification, cloud computing and social data security as well as “big data” management and analysis.